Dr. Dennis Marcus discusses how the PDS with ranibizumab fits into the treatment landscape and explores other sustained delivery mechanisms currently in development for neovascular AMD.
How does the PDS with ranibizumab fit into the treatment landscape that also includes highly durable agents such as faricimab and high-dose aflibercept?
What other sustained delivery mechanisms are currently in development for neovascular AMD?